IL143266A0 - Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same - Google Patents
Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the sameInfo
- Publication number
- IL143266A0 IL143266A0 IL14326699A IL14326699A IL143266A0 IL 143266 A0 IL143266 A0 IL 143266A0 IL 14326699 A IL14326699 A IL 14326699A IL 14326699 A IL14326699 A IL 14326699A IL 143266 A0 IL143266 A0 IL 143266A0
- Authority
- IL
- Israel
- Prior art keywords
- bone mineral
- pharmaceutical compositions
- growth factor
- same
- binding proteins
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title abstract 2
- 229910052500 inorganic mineral Inorganic materials 0.000 title 1
- 239000011707 mineral Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000029947 transforming growth factor beta binding proteins Human genes 0.000 title 1
- 108091014793 transforming growth factor beta binding proteins Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11028398P | 1998-11-27 | 1998-11-27 | |
PCT/US1999/027990 WO2000032773A1 (en) | 1998-11-27 | 1999-11-24 | Compositions and methods for increasing bone mineralization |
Publications (1)
Publication Number | Publication Date |
---|---|
IL143266A0 true IL143266A0 (en) | 2002-04-21 |
Family
ID=22332193
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14326699A IL143266A0 (en) | 1998-11-27 | 1999-11-24 | Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same |
IL143266A IL143266A (en) | 1998-11-27 | 2001-05-21 | Antibodies that bind β – TGF-binding proteins with a 1– M 6 10 strain and their use |
IL210392A IL210392A (en) | 1998-11-27 | 2010-12-30 | A nucleic acid molecule that encodes a polypeptide that reduces bone mineral content |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL143266A IL143266A (en) | 1998-11-27 | 2001-05-21 | Antibodies that bind β – TGF-binding proteins with a 1– M 6 10 strain and their use |
IL210392A IL210392A (en) | 1998-11-27 | 2010-12-30 | A nucleic acid molecule that encodes a polypeptide that reduces bone mineral content |
Country Status (18)
Country | Link |
---|---|
US (12) | US6395511B1 (el) |
EP (3) | EP1721979B1 (el) |
JP (2) | JP4813660B2 (el) |
CN (2) | CN1333828B (el) |
AT (2) | ATE338120T2 (el) |
BR (1) | BRPI9915679B8 (el) |
CA (1) | CA2352532C (el) |
CY (3) | CY1106260T1 (el) |
DE (2) | DE69942782D1 (el) |
DK (3) | DK1133558T4 (el) |
ES (3) | ES2272093T5 (el) |
HK (2) | HK1044171B (el) |
IL (3) | IL143266A0 (el) |
MX (2) | MX343200B (el) |
NZ (3) | NZ512122A (el) |
PT (3) | PT1133558E (el) |
WO (1) | WO2000032773A1 (el) |
ZA (1) | ZA200104234B (el) |
Families Citing this family (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020042926A1 (en) * | 1998-10-28 | 2002-04-11 | Matzuk Martin M. | Ovary-specific genes and proteins |
IL143266A0 (en) | 1998-11-27 | 2002-04-21 | Darwin Discovery Ltd | Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same |
US20040009535A1 (en) * | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
AU3511100A (en) * | 1999-03-12 | 2000-10-04 | Regeneron Pharmaceuticals, Inc. | Novel nucleic acids and polypeptides |
US20030138902A1 (en) * | 1999-08-31 | 2003-07-24 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1857551A3 (en) * | 2000-06-01 | 2007-11-28 | Amgen Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
MXPA02011808A (es) * | 2000-06-01 | 2003-04-10 | Amgen Inc | Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos. |
US20040132021A1 (en) * | 2000-06-19 | 2004-07-08 | Wendy Balemans | Osteolevin gene polymorphisms |
WO2002033089A2 (en) * | 2000-10-05 | 2002-04-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ixodes scapularis tissue factor pathway inhibitor |
CA2468125A1 (en) * | 2001-10-24 | 2003-05-01 | Dgi Biotechnologies, Inc. | Target specific screening and its use for identifying target binders |
US7202102B2 (en) * | 2001-11-27 | 2007-04-10 | Jds Uniphase Corporation | Doped absorption for enhanced responsivity for high speed photodiodes |
EP1575481A4 (en) * | 2002-03-01 | 2010-01-06 | Celltech R & D Inc | PROCESS FOR INCREASING OR REDUCING THE BONE DENSITY |
WO2003087763A2 (en) * | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
US20040023356A1 (en) | 2002-06-14 | 2004-02-05 | Robb Krumlauf | Wise/Sost nucleic acid sequences and amino acid sequences |
US7585501B2 (en) * | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
PL378566A1 (pl) * | 2003-03-14 | 2006-05-02 | Celltech R & D, Inc. | Ligandy dla białek wiążących TGF-beta i ich zastosowania |
US20040197828A1 (en) * | 2003-03-26 | 2004-10-07 | Gaddy Dana P. | Method for diagnosis and treatment of bone turnover |
JP3848288B2 (ja) * | 2003-04-25 | 2006-11-22 | キヤノン株式会社 | 放射線画像撮影装置 |
EP1632249A4 (en) * | 2003-06-05 | 2007-12-26 | Nippon Shinyaku Co Ltd | OSTEOGENESIS PROMOTION AMPLIFIER AND SCREENING METHOD THEREFOR |
CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
US8461155B2 (en) * | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
WO2005063983A1 (en) * | 2003-12-29 | 2005-07-14 | Galapagos Genomics N.V. | Modulators of bone homeostasis identified in a high-throughput screen |
WO2005072403A2 (en) | 2004-01-28 | 2005-08-11 | The Regents Of The University Of California | Bone morphogenic protein binding peptide |
US8193312B2 (en) | 2004-01-28 | 2012-06-05 | The Regents Of The University Of California | Bone morphogenic protein binding peptide |
US8415302B2 (en) | 2004-01-28 | 2013-04-09 | The Regents Of The University Of California | Surgical applications for BMP binding protein |
EP1853283B1 (en) * | 2004-11-29 | 2015-09-16 | The Regents of The University of California | Activating extraction of demineralized bone matrix |
ITMI20050739A1 (it) * | 2005-04-22 | 2006-10-23 | Effebi Spa | Piastrina di connsessione valvola-attuatore |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
WO2006135734A2 (en) * | 2005-06-10 | 2006-12-21 | The Regents Of The University Of California | Compositions and methods for altering bone density and bone patterning |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
KR20180030264A (ko) * | 2005-11-23 | 2018-03-21 | 악셀레론 파마 인코포레이티드 | 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
US20100036091A1 (en) * | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
US20100015665A1 (en) * | 2006-11-10 | 2010-01-21 | Ucb Pharma S.A. | Antibodies and diagnostics |
SI3345607T1 (sl) | 2006-12-29 | 2023-03-31 | Ossifi-Mab Llc | Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE |
US20080200425A1 (en) * | 2007-02-16 | 2008-08-21 | Kurtz Seymour J | Methods and compositions for regulating bone mineral density |
MY149129A (en) * | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
WO2008157367A1 (en) * | 2007-06-15 | 2008-12-24 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
WO2009029795A1 (en) * | 2007-08-31 | 2009-03-05 | Amgen Inc. | Solid-state protein formulation |
CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
WO2009043049A2 (en) | 2007-09-27 | 2009-04-02 | Amgen Inc. | Pharmaceutical formulations |
TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素(sclerostin)抗體組合物及使用方法 |
EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
US20110044978A1 (en) * | 2007-12-14 | 2011-02-24 | Amgen Inc. | Method for treating bone fracture |
US9103836B2 (en) * | 2008-04-02 | 2015-08-11 | Tel Hashomer Medical Research Infrastructure And Services Ltd | Procollagen C-proteinase enhancer (PCPE) biomarker for bone formation |
US8518656B2 (en) | 2008-04-02 | 2013-08-27 | Ramot Tel-Aviv University Ltd. | Procollagen C-proteinase enhancer (PCPE) biomarker for bone formation |
US8198292B2 (en) * | 2008-07-03 | 2012-06-12 | Osteogenex, Inc. | Vinpocetine and eburnamonine derivatives for promoting bone growth, treating renal damage and cancer, and devices thereof |
WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
EP2445512B1 (en) | 2009-06-23 | 2018-08-29 | The Regents of The University of California | Enhancement of bmp retention |
CA2778105C (en) | 2009-10-23 | 2019-04-02 | Amgen Inc. | Vial adapter and system |
EP2558106A1 (en) | 2010-04-16 | 2013-02-20 | Novartis AG | Methods and compositions for improving implant osseointegration |
SG10201701869YA (en) | 2010-05-14 | 2017-04-27 | Amgen Inc | High concentration antibody formulations |
FI2575935T4 (fi) | 2010-06-07 | 2023-11-23 | Amgen Inc | Lääkeaineen vapautuslaite |
WO2012059598A2 (en) | 2010-11-05 | 2012-05-10 | Novartis Ag | Methods of treating rheumatoid arthritis using il-17 antagonists |
EA201391248A1 (ru) | 2011-03-01 | 2014-05-30 | Эмджен Инк. | Биспецифические связывающие агенты |
PE20140437A1 (es) | 2011-03-25 | 2014-04-17 | Amgen Inc | Formulaciones de anticuerpos |
CA2831100C (en) | 2011-03-31 | 2020-02-18 | Mark Dominis Holt | Vial adapter and system |
LT3404041T (lt) | 2011-04-19 | 2020-08-25 | Amgen Inc. | Osteoporozės gydymo būdas |
ES2725785T3 (es) | 2011-04-20 | 2019-09-27 | Amgen Inc | Aparato autoinyector |
JP2014515759A (ja) | 2011-04-29 | 2014-07-03 | ノバルティス アーゲー | 扁平上皮がんを治療する方法関連出願 |
US10538584B2 (en) | 2011-08-04 | 2020-01-21 | Amgen Inc. | Methods for treating bone gap defects |
DK3453711T3 (da) | 2011-09-02 | 2021-10-18 | Univ California | Llp2a-bisphosphonatkonjugater til behandling mod osteoporose |
EP3045190B1 (en) | 2011-10-14 | 2022-06-15 | Amgen Inc. | Injector and method of assembly |
JP6363954B2 (ja) | 2011-12-28 | 2018-07-25 | アムジエン・インコーポレーテツド | 抗スクレロスチン抗体の使用による歯槽骨消失の治療方法 |
EP2869844B2 (en) | 2012-07-05 | 2023-06-21 | UCB Pharma S.A. | Treatment for bone diseases |
AU2013348071B2 (en) | 2012-11-21 | 2018-05-24 | Amgen Inc. | Drug delivery device |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
ES2973257T3 (es) | 2013-03-15 | 2024-06-19 | Amgen Inc | Casete de fármaco, autoinyector y sistema de autoinyector |
BR112015022042B1 (pt) | 2013-03-15 | 2023-01-10 | Amgen Inc | Injetor para injetar um produto terapêutico |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
TWI580452B (zh) | 2013-03-15 | 2017-05-01 | 安美基公司 | 用於注射器之匣盒、注射器及使用包括自動注射器及匣盒之設備之方法 |
MX369360B (es) | 2013-03-20 | 2019-11-06 | Baylor College Medicine | ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I). |
ES2853748T3 (es) | 2013-03-22 | 2021-09-17 | Amgen Inc | Inyector y método de montaje |
WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
US11097055B2 (en) | 2013-10-24 | 2021-08-24 | Amgen Inc. | Injector and method of assembly |
EP3501575B1 (en) | 2013-10-24 | 2021-12-01 | Amgen Inc. | Drug delivery system with temperature-sensitive-control |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
EP3139977B1 (en) | 2014-05-07 | 2021-02-17 | Amgen Inc. | Autoinjector with shock reducing elements |
ES2981280T3 (es) | 2014-06-03 | 2024-10-08 | Amgen Inc | Sistema de administración de fármacos controlable y método de uso |
CA2957960C (en) | 2014-10-14 | 2023-08-22 | Amgen, Inc. | Drug injection device with visual and audible indicators |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
US11357916B2 (en) | 2014-12-19 | 2022-06-14 | Amgen Inc. | Drug delivery device with live button or user interface field |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
EP3258988B1 (en) | 2015-02-17 | 2019-08-28 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
ES2905870T3 (es) | 2015-02-27 | 2022-04-12 | Amgen Inc | Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
ES2755717T3 (es) | 2015-12-09 | 2020-04-23 | Amgen Inc | Autoinyector con tapa de señalización |
WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
US11200298B2 (en) | 2016-03-15 | 2021-12-14 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
JP7309363B2 (ja) | 2016-05-13 | 2023-07-18 | アムジエン・インコーポレーテツド | バイアル・スリーブ組立体 |
US11238150B2 (en) | 2016-05-16 | 2022-02-01 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190185556A1 (en) | 2016-08-08 | 2019-06-20 | Amgen Inc. | Method of improving connective tissue attachment using anti-sclerostin antibodies |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
EP3554256B1 (en) | 2016-12-15 | 2023-07-19 | Société des Produits Nestlé S.A. | Compositions and methods that modulate vitamin d and bone mineral content in a companion animal |
CN110325548B (zh) | 2016-12-21 | 2023-11-17 | 美莱奥生物制药第三有限公司 | 抗硬化蛋白抗体在治疗成骨不全症中的用途 |
US10961305B2 (en) | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
MX2019008432A (es) | 2017-01-17 | 2019-11-18 | Amgen Inc | Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje. |
AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
US11752258B2 (en) | 2017-02-17 | 2023-09-12 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
IL268478B2 (en) | 2017-03-07 | 2023-10-01 | Amgen Inc | Inserting a needle using super pressure |
US11986624B2 (en) | 2017-03-09 | 2024-05-21 | Amgen Inc. | Insertion mechanism for drug delivery device |
SG11201907676PA (en) | 2017-03-28 | 2019-09-27 | Amgen Inc | Plunger rod and syringe assembly system and method |
CN110709121B (zh) | 2017-06-08 | 2022-06-24 | 安进公司 | 扭矩驱动式药物递送装置 |
EP3634539A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
AU2018288604B2 (en) | 2017-06-22 | 2023-12-21 | Amgen Inc. | Device activation impact/shock reduction |
US11395880B2 (en) | 2017-06-23 | 2022-07-26 | Amgen Inc. | Electronic drug delivery device |
WO2019014014A1 (en) | 2017-07-14 | 2019-01-17 | Amgen Inc. | NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM |
US11672733B2 (en) | 2017-07-21 | 2023-06-13 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
JP2020528296A (ja) | 2017-07-25 | 2020-09-24 | アムジエン・インコーポレーテツド | ギヤモジュールを有する薬物送達デバイス及び関連する組立方法 |
EP3658206A1 (en) | 2017-07-25 | 2020-06-03 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
MA49838A (fr) | 2017-08-09 | 2020-06-17 | Amgen Inc | Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre |
US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
MA50611A (fr) | 2017-10-04 | 2020-08-12 | Amgen Inc | Adaptateur d'écoulement destiné à un dispositif d'administration de médicament |
MA50614A (fr) | 2017-10-06 | 2020-08-12 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé |
IL273323B2 (en) | 2017-10-09 | 2024-10-01 | Amgen Inc | Drug delivery device with drive assembly and related assembly method |
MA50528A (fr) | 2017-11-03 | 2020-09-09 | Amgen Inc | Systèmes et approches pour stériliser un dispositif d'administration de médicament |
MA50569A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Ensembles de remplissage-finition et procédés associés |
EP3706830B1 (en) | 2017-11-06 | 2024-08-07 | Amgen Inc. | Drug delivery device with placement and flow sensing |
EP3706826A1 (en) | 2017-11-10 | 2020-09-16 | Amgen Inc. | Plungers for drug delivery devices |
MX2020005066A (es) | 2017-11-16 | 2020-08-20 | Amgen Inc | Autoinyector con deteccion de detencion y punto final. |
CN111278487B (zh) | 2017-11-16 | 2022-06-24 | 安进公司 | 用于药物递送装置的门闩锁机构 |
AU2019243595A1 (en) | 2018-03-30 | 2020-09-17 | Amgen Inc. | C-terminal antibody variants |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
WO2020023451A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
MX2021000748A (es) | 2018-07-24 | 2021-03-26 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
CA3103105A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
MA53272A (fr) | 2018-08-10 | 2021-11-17 | Amgen Inc | Procédé de préparation d'une formulation pharmaceutique d'anticorps |
MA53724A (fr) | 2018-09-24 | 2021-12-29 | Amgen Inc | Systèmes et procédés de dosage interventionnel |
WO2020068476A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
MX2021003492A (es) | 2018-10-02 | 2021-06-18 | Amgen Inc | Sistemas de inyeccion para la administracion de farmacos con transmision de fuerza interna. |
JP7547325B2 (ja) | 2018-10-05 | 2024-09-09 | アムジエン・インコーポレーテツド | 投薬量インジケータを有する薬物送達デバイス |
TWI846741B (zh) | 2018-10-15 | 2024-07-01 | 美商安進公司 | 用於藥物遞送裝置之平台組裝方法 |
EP3866890A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Drug delivery device having damping mechanism |
AU2019370159A1 (en) | 2018-11-01 | 2021-04-22 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
US20220160972A1 (en) | 2019-04-24 | 2022-05-26 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
US20220275073A1 (en) | 2019-08-12 | 2022-09-01 | Amgen Inc. | Anti-Sclerostin Antibody Formulations |
EP4017560A2 (en) | 2019-08-23 | 2022-06-29 | Amgen, Inc | Drug delivery device with configurable needle shield engagement components and related methods |
KR20230117177A (ko) * | 2020-12-03 | 2023-08-07 | 유니버시티 오브 매사추세츠 | 진행성 골화성 섬유이형성증을 위한 신규 유전자 치료제의개발 |
CN113354724A (zh) * | 2021-04-28 | 2021-09-07 | 蒋青 | 骨硬化蛋白及其在制备治疗或预防阿尔兹海默症的相关产品上应用 |
IL307418A (en) | 2021-05-21 | 2023-12-01 | Amgen Inc | A method for optimizing a filling recipe for a drug container |
Family Cites Families (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US649445A (en) * | 1899-08-31 | 1900-05-15 | James Alpheus Green | Steam-injector for fire-boxes of steam-boilers. |
US4018884A (en) | 1975-06-26 | 1977-04-19 | Hoffmann-La Roche Inc. | Fluorogenic materials and labeling techniques |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4378110A (en) * | 1978-04-17 | 1983-03-29 | Greene Ronald W | Continuous paper sorting machine |
US4359535A (en) | 1979-10-01 | 1982-11-16 | George Pieczenik | Autonomously replicating DNA containing inserted DNA sequences |
US4528266A (en) | 1979-10-01 | 1985-07-09 | George Pieczenik | Method of inserting unique DNA sequences into DNA vectors |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4427115A (en) * | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
DE3417525C1 (de) * | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
US5087571A (en) | 1984-06-22 | 1992-02-11 | President And Fellows Of Harvard College | Method for providing a cell culture from a transgenic non-human mammal |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US4801542A (en) | 1984-10-12 | 1989-01-31 | Zymogenetics, Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
SG64329A1 (en) | 1984-11-16 | 1999-04-27 | American Cyanamid Co | Antitumor antibiotics (LL-E33288 complex) |
US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US4897255A (en) | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
CA1293460C (en) | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
US4744981A (en) | 1985-10-17 | 1988-05-17 | Neorx Corporation | Trichothecene antibody conjugates |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
EP0289121B1 (en) | 1987-05-01 | 1995-12-27 | Stratagene | Mutagenesis testing using transgenic non-human animals carrying test DNA sequences |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
ATE112172T1 (de) | 1987-10-30 | 1994-10-15 | American Cyanamid Co | Targetformer von antitumor-methyltrithioagenzien. |
US5254678A (en) | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
EP0329184A3 (en) | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimers and antimeric conjugation |
US4988496A (en) | 1988-05-31 | 1991-01-29 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
US5221778A (en) | 1988-08-24 | 1993-06-22 | Yale University | Multiplex gene regulation |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
JP2752788B2 (ja) | 1989-01-23 | 1998-05-18 | カイロン コーポレイション | 感染および過剰増殖障害の為の組換え療法 |
GB8903022D0 (en) | 1989-02-10 | 1989-03-30 | Celltech Ltd | Chemical compounds |
US5175383A (en) | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
US5549910A (en) * | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
GB8914543D0 (en) | 1989-06-23 | 1989-08-09 | Parker David | Chemical compounds |
JP4041535B2 (ja) | 1989-08-18 | 2008-01-30 | オックスフォード バイオメディカ(ユーケー)リミテッド | 標的細胞にベクター構造体を運搬する組換レトロウィルス |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5359051A (en) | 1990-01-11 | 1994-10-25 | Isis Pharmaceuticals | Compounds useful in the synthesis of nucleic acids capable of cleaning RNA |
EP0438803B1 (en) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
US5177197A (en) * | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
US5466468A (en) * | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
ES2217250T3 (es) | 1990-06-15 | 2004-11-01 | Scios Inc. | Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer. |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP3218637B2 (ja) * | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
WO1992002551A1 (en) * | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
JP2958076B2 (ja) * | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5698426A (en) * | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗hiv改変抗体および改変抗体の調製方法 |
US5070108A (en) * | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
CA2094608A1 (en) | 1990-10-22 | 1992-04-23 | John D. Taylor | Dna construct for providing rna therapy |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
JP4146512B2 (ja) | 1991-03-01 | 2008-09-10 | ダイアックス コープ. | 小型タンパク質 |
US6949505B1 (en) * | 1991-03-11 | 2005-09-27 | Curis, Inc. | Morphogen-induced dendritic growth |
RU2139351C1 (ru) | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
US5203975A (en) | 1991-10-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Process for cathodic electrodeposition of a clear coating over a conductive paint layer |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION. |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
IL108719A0 (en) | 1993-02-25 | 1994-08-26 | Ortho Pharma Corp | Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them |
FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
EP0708659A4 (en) * | 1993-06-07 | 2000-08-23 | Genentech Inc | HIV ENVELOPE POLYPEPTIDE |
JPH09506857A (ja) | 1993-07-16 | 1997-07-08 | オントーゲン コーポレーション | 多成分組合せアレイ合成による有機化合物の組合せアレイの合成 |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5453492A (en) * | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
JPH09504511A (ja) | 1993-08-03 | 1997-05-06 | イーライ リリィ アンド カンパニー | 構造的に多様なユニバーサルライブラリーから医薬として有用な非ペプチド化合物を製造するためのおよび選択するための方法 |
US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
WO1995013365A1 (en) | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
WO1995016209A1 (en) | 1993-12-09 | 1995-06-15 | Ciba-Geigy Ag | Process for the production of combinatorial compound libraries |
EP0734530B1 (en) | 1993-12-15 | 1997-11-12 | Combichem, Inc. | Combinatorial libraries and methods for their use |
WO1995016712A1 (en) | 1993-12-15 | 1995-06-22 | Smithkline Beecham Corporation | Compounds and methods |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
EP0751765B1 (en) | 1994-03-11 | 2003-05-07 | Pharmacopeia, Inc. | Sulfonamide derivatives and their use |
ATE378407T1 (de) | 1994-04-29 | 2007-11-15 | Curis Inc | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen |
JPH10500112A (ja) | 1994-05-06 | 1998-01-06 | ファーマコピーア,インコーポレイテッド | 組合せ ジヒドロベンゾピラン ライブラリー |
US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
DE4427221A1 (de) | 1994-08-01 | 1996-02-08 | Gsf Forschungszentrum Umwelt | Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie |
US5463564A (en) | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
US6057421A (en) * | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
IE80468B1 (en) * | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
EP0871705A4 (en) | 1995-06-05 | 2000-01-26 | Human Genome Sciences Inc | CCN TYPE HUMAN GROWTH FACTOR |
US5738868A (en) * | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
JP4124486B2 (ja) * | 1996-05-22 | 2008-07-23 | ビベンティア バイオテック インコーポレイテッド | ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用 |
US5989912A (en) | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
US6133426A (en) * | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
WO1998046588A2 (en) * | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
AU726385B2 (en) * | 1997-04-29 | 2000-11-02 | Regeneron Pharmaceuticals, Inc. | Human cerberus protein |
JP3614866B2 (ja) * | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
CA2297109A1 (en) * | 1997-08-01 | 1999-02-11 | Genset | 5' ests for secreted proteins expressed in muscle and other mesodermal tissues |
US6815201B2 (en) * | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
US6544485B1 (en) * | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
US20040009535A1 (en) * | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
IL143266A0 (en) | 1998-11-27 | 2002-04-21 | Darwin Discovery Ltd | Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same |
IL144578A0 (en) | 1999-01-29 | 2002-05-23 | Imclone Systems Inc | Antibodies specific to kdr and uses thereof |
EP1683811B1 (en) | 1999-06-09 | 2009-08-19 | Genentech, Inc. | Methods for the diagnosis of tumors |
JP4141095B2 (ja) | 1999-10-29 | 2008-08-27 | 三洋電機株式会社 | 半導体装置とその製造方法 |
AU2001241968B2 (en) | 2000-03-02 | 2005-09-15 | Amgen Inc. | Chordin-like-2 molecules and uses thereof |
MXPA02011808A (es) * | 2000-06-01 | 2003-04-10 | Amgen Inc | Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos. |
US20040132021A1 (en) | 2000-06-19 | 2004-07-08 | Wendy Balemans | Osteolevin gene polymorphisms |
EP1341814A2 (en) | 2000-09-01 | 2003-09-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU1344102A (en) | 2000-10-12 | 2002-04-22 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2374027A1 (en) * | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
DE10145772A1 (de) | 2001-09-17 | 2003-04-10 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
WO2003050513A2 (en) | 2001-12-06 | 2003-06-19 | Biocontrol Systems, Inc. | Sample collection and testing system |
US20030186915A1 (en) * | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
EP1575481A4 (en) | 2002-03-01 | 2010-01-06 | Celltech R & D Inc | PROCESS FOR INCREASING OR REDUCING THE BONE DENSITY |
WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
FR2838379B1 (fr) | 2002-04-12 | 2005-06-24 | Valeo Climatisation | Dispositif de purification de l'air de l'habitacle d'un vehicule automobile |
US20040023356A1 (en) * | 2002-06-14 | 2004-02-05 | Robb Krumlauf | Wise/Sost nucleic acid sequences and amino acid sequences |
US7893218B2 (en) * | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
EP1572122A4 (en) | 2002-11-01 | 2008-04-09 | Us Gov Health & Human Serv | METHOD FOR PREVENTING INFECTIONS FROM BIOLOGICAL TERRORISM AGENTS WITH IMMUNOSTIMULATORY CPG OLIGONUCLEOTIDES |
DE10255152A1 (de) | 2002-11-26 | 2004-06-03 | Von Langen Ursula Lang | Schadstoffsauger |
US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
US20040141875A1 (en) * | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
PL378566A1 (pl) | 2003-03-14 | 2006-05-02 | Celltech R & D, Inc. | Ligandy dla białek wiążących TGF-beta i ich zastosowania |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
US20050267233A1 (en) | 2004-05-25 | 2005-12-01 | Joshi Ashok V | Anti-microbial handle system |
MX2007001221A (es) | 2004-08-04 | 2007-03-23 | Amgen Inc | Anticuerpos para proteina dickkopf-1 (dkk-1). |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
WO2007080129A1 (en) | 2006-01-13 | 2007-07-19 | A Chan Holding B.V. | Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction |
US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
US20100015665A1 (en) | 2006-11-10 | 2010-01-21 | Ucb Pharma S.A. | Antibodies and diagnostics |
SI3345607T1 (sl) | 2006-12-29 | 2023-03-31 | Ossifi-Mab Llc | Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE |
CN101616684A (zh) | 2007-02-02 | 2009-12-30 | 诺瓦提斯公司 | 用于治疗骨相关病症的硬化蛋白结合配偶体调节剂 |
MY149129A (en) | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素(sclerostin)抗體組合物及使用方法 |
EP2209491B1 (en) | 2007-11-02 | 2015-10-28 | Novartis AG | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6) |
US20110044978A1 (en) | 2007-12-14 | 2011-02-24 | Amgen Inc. | Method for treating bone fracture |
WO2009149189A2 (en) | 2008-06-03 | 2009-12-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
AR075715A1 (es) | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
US9879072B2 (en) | 2010-10-27 | 2018-01-30 | Amgen Inc. | DKK1 antibodies and methods of use |
-
1999
- 1999-11-24 IL IL14326699A patent/IL143266A0/xx active IP Right Grant
- 1999-11-24 ES ES99963986.7T patent/ES2272093T5/es not_active Expired - Lifetime
- 1999-11-24 PT PT99963986T patent/PT1133558E/pt unknown
- 1999-11-24 DK DK99963986.7T patent/DK1133558T4/en active
- 1999-11-24 CN CN99815505.5A patent/CN1333828B/zh not_active Expired - Lifetime
- 1999-11-24 DK DK06011535.9T patent/DK1721979T3/da active
- 1999-11-24 MX MX2013001685A patent/MX343200B/es unknown
- 1999-11-24 DK DK10008049.8T patent/DK2261335T3/en active
- 1999-11-24 PT PT06011535T patent/PT1721979E/pt unknown
- 1999-11-24 JP JP2000585404A patent/JP4813660B2/ja not_active Expired - Lifetime
- 1999-11-24 EP EP06011535A patent/EP1721979B1/en not_active Revoked
- 1999-11-24 AT AT99963986T patent/ATE338120T2/de active
- 1999-11-24 NZ NZ512122A patent/NZ512122A/en not_active IP Right Cessation
- 1999-11-24 EP EP10008049.8A patent/EP2261335B1/en not_active Expired - Lifetime
- 1999-11-24 CN CN2008100992340A patent/CN101469329B/zh not_active Expired - Lifetime
- 1999-11-24 CA CA2352532A patent/CA2352532C/en not_active Expired - Lifetime
- 1999-11-24 DE DE69942782T patent/DE69942782D1/de not_active Expired - Lifetime
- 1999-11-24 ES ES10008049.8T patent/ES2639020T3/es not_active Expired - Lifetime
- 1999-11-24 ES ES06011535T patent/ES2350454T3/es not_active Expired - Lifetime
- 1999-11-24 AT AT06011535T patent/ATE481487T1/de active
- 1999-11-24 WO PCT/US1999/027990 patent/WO2000032773A1/en active Application Filing
- 1999-11-24 MX MXPA01005275A patent/MXPA01005275A/es active IP Right Grant
- 1999-11-24 NZ NZ552959A patent/NZ552959A/en not_active IP Right Cessation
- 1999-11-24 US US09/449,218 patent/US6395511B1/en not_active Expired - Lifetime
- 1999-11-24 DE DE69933044.0T patent/DE69933044T3/de not_active Expired - Lifetime
- 1999-11-24 EP EP99963986.7A patent/EP1133558B2/en not_active Expired - Lifetime
- 1999-11-24 PT PT100080498T patent/PT2261335T/pt unknown
- 1999-11-24 BR BRPI9915679A patent/BRPI9915679B8/pt not_active IP Right Cessation
- 1999-11-24 NZ NZ568033A patent/NZ568033A/en not_active IP Right Cessation
-
2000
- 2000-09-21 US US09/668,037 patent/US6495736B1/en not_active Expired - Lifetime
- 2000-09-21 US US09/668,529 patent/US6489445B1/en not_active Expired - Lifetime
- 2000-09-21 US US09/668,021 patent/US6803453B1/en not_active Expired - Lifetime
-
2001
- 2001-05-21 IL IL143266A patent/IL143266A/en not_active IP Right Cessation
- 2001-05-23 ZA ZA200104234A patent/ZA200104234B/en unknown
-
2002
- 2002-03-07 US US10/095,248 patent/US7572899B2/en not_active Expired - Fee Related
- 2002-07-26 HK HK02105515.3A patent/HK1044171B/zh not_active IP Right Cessation
-
2003
- 2003-03-06 US US10/384,893 patent/US7192583B2/en not_active Expired - Lifetime
-
2004
- 2004-02-27 US US10/788,606 patent/US7758858B2/en not_active Expired - Fee Related
-
2006
- 2006-11-09 CY CY20061101623T patent/CY1106260T1/el unknown
-
2007
- 2007-10-31 US US11/931,853 patent/US20110150866A1/en not_active Abandoned
- 2007-10-31 US US11/931,812 patent/US7977312B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/931,768 patent/US7994299B2/en not_active Expired - Fee Related
-
2009
- 2009-12-31 HK HK09112388.6A patent/HK1135726A1/xx not_active IP Right Cessation
-
2010
- 2010-12-10 CY CY20101101148T patent/CY1110982T1/el unknown
- 2010-12-30 IL IL210392A patent/IL210392A/en not_active IP Right Cessation
-
2011
- 2011-06-30 JP JP2011145326A patent/JP5691036B2/ja not_active Expired - Lifetime
-
2012
- 2012-10-04 US US13/644,728 patent/US8986685B2/en not_active Expired - Fee Related
-
2015
- 2015-02-19 US US14/626,274 patent/US9791462B2/en not_active Expired - Fee Related
-
2017
- 2017-08-30 CY CY20171100914T patent/CY1119263T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL143266A0 (en) | Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same | |
MXPA03011236A (es) | Vehiculos de liberacion de fosfato de calcio para proteinas osteoinductivas. | |
ATE258984T1 (de) | Bmp-11 zusammensetzungen | |
AU2002305450A1 (en) | Proteomimetic compounds and methods | |
DE60004496D1 (de) | Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff | |
WO1998021972A3 (de) | Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender aktivität | |
ATE338569T1 (de) | Osteogene vorrichtungen und verfahren zu ihrer verwendung zur knochenreparatur | |
WO1997035023A3 (en) | Alteration of amino acid compositions in seeds | |
WO2003011898A3 (fr) | Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations | |
TW200518767A (en) | Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins | |
AP9801269A0 (en) | Prostaglandin agonists. | |
IL134330A0 (en) | Heparin-binding growth factor (hbgf) polypeptides | |
ATE256740T1 (de) | Menschliches sdf-5 protein und diesbezügliche zusammensetzungen | |
WO1999024058A3 (en) | Neuronal uses of bmp-11 | |
EP1399023A4 (en) | COMPOSITIONS AND METHODS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES THAT CODE FOR BONE MORPHOGENESIS PROTEINS | |
AU3711597A (en) | A novel galanin receptor | |
WO2003025179A1 (en) | Novel polypeptide, dna thereof and use of the same | |
KR100256319B1 (en) | Stem cell proliferation factor | |
WO1998002557A3 (en) | MAMMALIAN TNF-α CONVERTASES | |
SE9604439D0 (sv) | New receptor | |
WO2001021794A3 (en) | Smad associating polypeptides | |
PL1704237T3 (pl) | Ccamk biorąca udział w nodulacji i endomikoryzacji |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted |